Patient-reported outcomes from a phase 2 PLATINUM trial of nivolumab combination therapy sparing concurrent cisplatin in nasopharyngeal carcinoma - PubMed
8 days ago
- #patient-reported outcomes
- #nasopharyngeal carcinoma
- #quality of life
- The PLATINUM trial evaluated nivolumab plus chemoradiotherapy sparing concurrent cisplatin in nasopharyngeal carcinoma (NPC), showing efficacy and safety.
- Patient-reported outcomes (PROs) focused on quality of life (QoL), tolerability, and social reintegration were assessed.
- Among 152 patients, 44.1% achieved social reintegration, and 51.3% were satisfied with their current life.
- Radiotherapy had a more significant negative impact on QoL than induction chemotherapy, while its removal improved QoL more than nivolumab removal.
- Patients without social reintegration experienced greater deterioration in speech and swallowing functions.
- Under-reporting of decreased appetite severity by clinicians vs. patients was linked to poorer social reintegration and reduced failure-free survival.
- Social reintegration is a practical composite indicator of favorable PROs in NPC, with interventions targeting speech, swallowing, and appetite potentially improving recovery.